<DOC>
	<DOC>NCT00041470</DOC>
	<brief_summary>The purposes of this are: - To determine the highest doses of Taxol and Navelbine that we can safely give to patients; - To determine what kind of side effects are caused by the combination of Taxol, Navelbine and G-CSF; - To determine whether the combination of Taxol, Navelbine and G-CSF is more effective than standard therapy in treating metastatic breast cancer and prolonging life;</brief_summary>
	<brief_title>Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>INCLUSION To be eligible, volunteers must: Have stage IV carcinoma of the breast that has been microscopically confirmed Be age &gt; 18 Be fully active or ambulatory with symptoms but able to do light work Have a life expectancy of &gt; 16 weeks Be &gt; 2 weeks from prior surgery; &gt; 3 weeks from radiation therapy to the pelvis, spine or long bones; &gt; 3 weeks from prior chemotherapy (&gt; 6 weeks for mitomycin C or nitrosureas) and &gt; 2 weeks from prior hormonal therapy Have had one or less prior regimens for metastatic disease Have measurable (bidimensionally) or evaluable disease that is in an area that has not been radiated EXCLUSION Patients are not eligible if they: Have rapidly progressing liver or lung metastases or uncontrolled central nervous system metastases Are medically unstable Are pregnant, nursing or unwilling to employ adequate contraception Have preexisting clinically significant peripheral neuropathy except for abnormalities due to cancer Have psychological, familial, sociological or geographical conditions that do not permit weekly medical followup and compliance with the study protocol Have hypersensitivity to E. Coliderived proteins, Filgrastim, or any of its components Have had prior therapy with Navelbine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>